Senior insider sale
CFO at REVANCE THERAPEUTICS, INC. — senior position signals high conviction
$980.8K
29.50K shares
What this filing means
SCHILKE TOBIN plans to sell 29.50K shares of REVANCE THERAPEUTICS, INC. valued at approximately $980.8K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 7/3/2023ACC: 0001950047-23-002099
Officer· CFO
Since Nov 2018
29.50K
Shares to sell
$980.8K
Approx. market value
1.70K
Acquired (3 months)
1
Planned
4 completed
Securities Acquired — Last 3 Months1
Restricted Stock
Not Applicable
2/15/2021
1.70KTotal acquired1.70K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
2/15/2021 | Restricted Stock Not Applicable | 1.70K | — |
| Total | 1.70K | ||
Planned & Completed Dispositions5
Completed
—Completed
Units to sell
500.00
Market value
$15.5K
6/2/2023
—Completed
Units to sell
2.70K
Market value
$82.6K
6/1/2023
—Completed
Units to sell
21.40K
Market value
$738.7K
5/15/2023
—Completed
Units to sell
3.20K
Market value
$101.5K
5/1/2023
Planned — Approximate Date
NASDPlanned
Units to sell
1.70K
Market value
$42.6K
7/3/2023
Total
Units
29.50K
Value
$980.8K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
6/2/2023 | 500.00 | $15.5K | — | Completed |
6/1/2023 | 2.70K | $82.6K | — | Completed |
5/15/2023 | 21.40K | $738.7K | — | Completed |
5/1/2023 | 3.20K | $101.5K | — | Completed |
| Planned — Approximate Date | ||||
7/3/2023 | 1.70K | $42.6K | NASD | Planned |
| Total | 29.50K | $980.8K | ||